PI3k kinase and scaffold functions in heart

Annals of the New York Academy of Sciences

Volumn 1188, Issue , 2010, Pages 39-45

  Damilano, Federico ^a   Perino, Alessia ^a   Hirsch, Emilio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Failure; Heart; Hypertrophy; Phosphoinositide 3 kinase; Signal transduction

Indexed keywords

BETA ADRENERGIC RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; TYROSINE KINASE RECEPTOR;

CONFERENCE PAPER; ENZYME ACTIVITY; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MUSCLE FIBER CONTRACTION; NONHUMAN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 77649167710     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05081.x     Document Type: Conference Paper

References (38)

1. Van Haesebroeck, B. et al. 2001. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70: 535-602.
2. DiNitto, J.P. & D.G. Lambright. 2006. Membrane and juxtamembrane targeting by PH and PTB domains. Biochim. Biophys. Acta 1761: 850-867. (Pubitemid 44332328) (Pubitemid 44332328)
3. Chan, T.O., S.E. Rittenhouse & P.N. Tsichlis. 1999. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositidedependent phosphorylation. Annu. Rev. Biochem. 68: 965-1014. (Pubitemid 29449213) (Pubitemid 29449213)
4. Hanada, M., J. Feng & B.A. Hemmings. 2004. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim. Biophys. Acta 1697: 3-16. (Pubitemid 38326757) (Pubitemid 38326757)
5. Stoyanova, S. et al. 1997. Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase gamma: structure-activity analysis and interactions with wortmannin. Biochem. J. 324(Pt 2): 489-495. (Pubitemid 27267992)
6. McMullen, J.R. et al. 2003. Phosphoinositide 3kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 100: 12355-12360.
7. Patrucco, E. et al. 2004. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118: 375-387. (Pubitemid 39061117) (Pubitemid 39061117)
8. Crackower, M.A. et al. 2002. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110: 737-749.
9. Condorelli, G. et al. 2002. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl. Acad. Sci. USA 99: 12333-12338.
10. DeBosch, B. et al. 2006. Akt1 is required for physiological cardiac growth. Circulations: 2097-2104. (Pubitemid 43755160) (Pubitemid 43755160)
11. Matsui, T. et al. 2002. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem. 277: 22896-22901. (Pubitemid 34967272) (Pubitemid 34967272)
12. Shioi, T. et al. 2002. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 11: 2799-2809.
13. Kim, Y.K. et al. 2003. Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt. J. Biol. Chem. 278: 47622-47628.
14. 2+ currents via increased PI3Kalpha/PKB signaling. Circ. Res. 98: 1390-1397.
15. Mc Mullen, J.R. et al. 2007. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA 104: 612-617.
16. MacLennan, D.H., M. Asahi & A.R. Tupling. 2003. The regulation of SERCA-type pumps by phospholamban and sarcolipin. Ann. N. Y. Acad. Sci. 986: 472-480.
17. Mac Lennan, D.H. & E.G. Kranias. 2003. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell. Biol. 4: 566-577.
18. Kerfant, B.G. et al. 2007. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ. Res. 101: 400-408.
19. 2+ channel regulation in guinea-pig ventricular myocytes. J. Physiol. 580: 765-776.
20. Emter, C.A. et al. 2005. Low-intensity exercise training delays onset of decompensated heart failure in spontaneously hypertensive heart failure rats. Am. J. Physiol. Heart Circ. Physiol. 289: H2030-2038.
21. Lowes, B.D. et al. 1997. Changes in gene expression in the intact human heart: downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J. Clin. Invest. 100: 2315-2324.
22. Weis, W.I. & B.K. Kobilka. 2008. Structural insights into G-protein-coupled receptor activation. Curr. Opin. Struct. Biol. 18: 734-740.
23. Brodde, O.E., H. Brück & K. Leineweber. 2006. Cardiac adrenoceptors: physiological and pathophysiological relevance. J. Pharmacol. Sci. 100: 323-337.
24. 2+ current. J. Clin. Invest. 118: 3219-3227.
25. Rockman, H.A., W.J. Koch & R.J. Lefkowitz. 2002. Seventransmembrane- spanning receptors and heart function. Nature 415: 206-212.
26. Ferguson, S.S. 2001. Evolving concepts in G proteincoupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53: 1-24.
27. Naga Prasad, S.V. et al. 2001. Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1: a role in receptor sequestration. J. Biol. Chem. 276: 18953-18959. (Pubitemid 37411217)
28. Iaccarino, G. et al. 1998. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation 98: 1783-1789. (Pubitemid 28492500)
29. Naga Prasad, S.V. et al. 2002. Phosphoinositide 3-kinase regulates beta 2-adrenergic receptor endocytosis by AP2 recruitment to the receptor/beta- arrestin complex. J. Cell Biol. 158: 563-575.
30. Nienaber, J. J. et al. 2003. Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. J. Clin. Invest. 112: 1067-1079.
31. Naga Prasad, S.V. et al. 2000. Gbeta gamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J. Biol. Chem. 275: 4693-11698
32. Naga Prasad, S.V. et al. 2005. Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis. Nat. Cell Biol. 7: 785-796.
33. Lefkowitz,RJ. & E.J.Whalen. 2004. Beta-arrestins:traffic cops of cell signaling. Curr. Opin. Cell Biol. 16: 162-168.
34. Perrino, C. et al. 2005. Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3kinase complex. Circulation 111: 2579-2587. (Pubitemid 40740856) (Pubitemid 40740856)
35. Ban, K. et al. 2008. Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ. Res. 103: 643-653.
36. Murry, C.E., R.B. Jennings &K.A. Reimer. 1986. Precon-ditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136.
37. Heymans, S. et al. 2009. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 11: 119-129.
38. Doukas, J. et al. 2006. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl. Acad. Sci. USA 103: 19866-19871. (Pubitemid 46037522) (Pubitemid 46037522)